Continued diabetes medicines after bariatric surgery in adults with type 2 diabetes
Tests keeping diabetes medicines after weight-loss surgery in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
Key facts
- Where
- Dublin, IrelandSee the site
Where in Ireland
- University College DublinDublin, IrelandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imperial College London
- Trial code
- NCT04432025
- Record updated
- 8 August 2022
- Original description
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.Read full original descriptionShow less
Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.
Inclusion: eligible for bariatric surgery according to NICE guidelines (GC 189); Type 2 diabetes mellitus; BMI >30kg/m2.
Exclusion: Contraindications to bariatric surgery; Previous bariatric surgery; Recent hospitalisation in the past 30 days; Recurrent hypoglycaemic episodes; Recurrent hypotensive episodes; Current pregnancy; Breastfeeding.